Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Conditions
- Post-transplant Lymphoproliferative Disorder
Interventions
- DRUG: Loncastuximab tesirine
- DRUG: Rituximab or rituximab biosimilar
Sponsor
University of Utah
Collaborators